Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSCW) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to $363308.0.

  • Ensysce Biosciences' Change in Accured Expenses rose 79834.33% to $363308.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $890659.0, marking a year-over-year increase of 35459.62%. This contributed to the annual value of $43927.0 for FY2024, which is 10342.05% up from last year.
  • As of Q3 2025, Ensysce Biosciences' Change in Accured Expenses stood at $363308.0, which was up 79834.33% from -$37009.0 recorded in Q2 2025.
  • Ensysce Biosciences' Change in Accured Expenses' 5-year high stood at $2.2 million during Q3 2021, with a 5-year trough of -$987997.0 in Q2 2023.
  • Moreover, its 5-year median value for Change in Accured Expenses was $50134.0 (2022), whereas its average is $140737.4.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 53522.76% in 2023, then skyrocketed by 79834.33% in 2025.
  • Quarter analysis of 5 years shows Ensysce Biosciences' Change in Accured Expenses stood at -$323228.0 in 2021, then surged by 115.51% to $50134.0 in 2022, then crashed by 535.23% to -$218197.0 in 2023, then soared by 180.46% to $175562.0 in 2024, then skyrocketed by 106.94% to $363308.0 in 2025.
  • Its last three reported values are $363308.0 in Q3 2025, -$37009.0 for Q2 2025, and $388798.0 during Q1 2025.